Free Trial

Evotec (EVO) Stock Forecast & Price Target

Evotec logo
$5.47 +0.37 (+7.25%)
(As of 11:22 AM ET)

Evotec - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
2
Buy
2

Based on 5 Wall Street analysts who have issued ratings for Evotec in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 2 have given a hold rating, and 2 have given a buy rating for EVO.

Consensus Price Target

$5.93
8.47% Upside
According to the 5 analysts' twelve-month price targets for Evotec, the average price target is $5.93. The highest price target for EVO is $8.00, while the lowest price target for EVO is $3.80. The average price target represents a forecasted upside of 8.47% from the current price of $5.47.
Get the Latest News and Ratings for EVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Evotec and its competitors.

Sign Up

EVO Analyst Ratings Over Time

TypeCurrent Forecast
11/16/23 to 11/15/24
1 Month Ago
10/17/23 to 10/16/24
3 Months Ago
8/18/23 to 8/17/24
1 Year Ago
11/16/22 to 11/16/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.93$5.93$7.00$14.00
Forecasted Upside8.47% Upside97.12% Upside114.72% Upside42.28% Upside
Consensus Rating
Hold
Hold
Hold
Buy

EVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Evotec Stock vs. The Competition

TypeEvotecMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.34% Upside26,222.24% Upside8.88% Upside
News Sentiment Rating
Neutral News

See Recent EVO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+106.99%
10/7/2024Jefferies Financial Group
2 of 5 stars
 DowngradeBuy ➝ Hold$8.70 ➝ $3.80+10.79%
8/8/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 DowngradeHold ➝ Sell
7/29/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$15.00 ➝ $6.00+25.52%
1/18/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSector Perform ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:43 AM ET.


EVO Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Evotec is $5.93, with a high forecast of $8.00 and a low forecast of $3.80.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVO, but not buy additional shares or sell existing shares.

According to analysts, Evotec's stock has a predicted upside of 8.47% based on their 12-month stock forecasts.

Over the previous 90 days, Evotec's stock had 1 downgrade by analysts.

Evotec has been rated by research analysts at HC Wainwright, and Jefferies Financial Group in the past 90 days.

Analysts like Evotec less than other "medical" companies. The consensus rating for Evotec is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EVO compares to other companies.


This page (NASDAQ:EVO) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners